TCF11 (also known as Nrf1 and LCR-F1) is a basic-region leucine-zipper (b-ZIP) transcription factor that is essential during embryonic development. We have carried out expression analysis at a number of developmental stages and ®nd that while there is some localized elevated expression between 8 and 9 days post coitum (dpc), the gene is widely expressed with a constant level of mRNA transcripts detectable in all tissues and at all stages examined. However, this does not re¯ect the speci®c nature of a TCF11 mutant phenotype (EMBO J. 17 (1998) 1779) which shows an essential role in foetal liver haematopoiesis. The speci®city of TCF11 function may be controlled at a posttranscriptional level including availability of, and speci®c interaction with, a range of potential heterodimerization partners. We therefore carried out expression analysis of four candidate partner molecules; the three small Maf genes and another bZIP transcription factor found to bind to TCF11 in a two-hybrid screen, ATF4. We show different patterns of expression for the three Maf genes during development with MafG being widely expressed, MafK expressed only later in development and in speci®c tissues, and no detection of MafF. ATF4 shows evidence of complex regulation during development and shows elevated expression in many of the same sites as TCF11. q
Results and discussion
TCF11 is a basic-region leucine-zipper (bZIP) transcription factor (also known as Nrf1 or LCR-F1) belonging to the CNC subfamily, which is characterized by a domain of extended similarity (CNC domain) amino-terminal to the basic region (Luna et al., 1994 (Luna et al., , 1995 Caterina et al., 1994; Chan et al., 1993) . It is most closely related to the erythroid speci®c factor p45NF-E2 (see Orkin, 1995, for review) and two other more widely expressed genes, Nrf2 (Moi et al., 1994) and Nrf3 (Kobayashi et al., 1999) .
TCF11 was ®rst suggested to play a role in erythropoiesis due to its similarity to p45NF-E2 and its ability to bind NF-E2 sites in the regulatory regions of erythroid-speci®c genes (Chan et al., 1993; Caterina et al., 1994) . However, TCF11 is widely expressed in adult tissues and cell lines (Luna et al., 1994; Chan et al., 1993; Caterina et al., 1994) . Very little is known about the speci®c functions of TCF11. We originally suggested that TCF11 may regulate genes through antioxidant response elements (AREs) based on its binding characteristics (Johnsen et al., 1998) and it has subsequently been directly implicated, as has Nrf2, in the control of stress response Jaiswal, 1996, 1998; Alam et al., 1999; Kwong et al., 1999) . It has also been implicated in cell speci®c regulation of the tumour necrosis factor-a gene Novotny et al., 1998) . Given the developmental roles of genes closely related to TCF11 in Drosophila (the homeotic gene cap'n'collar; Mohler et al., 1995) and Caenorhabditis elegans (the cell lineage determinant Skn-1; Blackwell et al., 1994) , we undertook an investigation of TCF11 during mouse development and murine TCF11 was cloned and characterized (Skammelsrud et al., 2000) . Inactivation of the locus independently by two other laboratories has shown that the gene is essential during development (Farmer et al., 1997; Chan et al., 1998) . However, any speci®c conclusions are complicated by the fact that the two experiments yielded quite different results. In the ®rst case the mutation was lethal at 6.5 days post coitum (dpc) when the embryos were completely blocked in an early phase of gastrulation, whereas in the second case lethality occurred at 16.5±17.5 dpc, resulting apparently from anaemia and indicating a role in early blood cell production in the developing liver.
To investigate the developmental expression of TCF11 in detail we carried out whole-mount in situ hybridization. At www.elsevier.com/locate/modo the earliest stages examined (7±7.5 dpc) TCF11 is expressed throughout the embryo in both embryonic and extraembryonic tissues (Fig. 1a) . The expression level appears to be uniform with the exception of an accumulation of labelling at the boundary between embryo proper and extra-embryonic tissues where the newly formed mesothelium divides the amniotic and coelomic cavities. At 8 dpc the embryo has acquired obvious polarity with the development of the head fold at the anterior end. At this stage, TCF11 is expressed uniformly in all cells (Fig. 1b) , (con®rmed by section, data not shown). However, at 8.25 dpc (Fig. 1c) TCF11 transcripts become differentially distributed with an obvious accumulation in the heart, the presumptive midbrain and the mesenchyme of the headfold. By 8.5 dpc (Fig. 1e) , elevated expression has become more pronounced throughout the head mesenchyme and is contributed to by elevated expression in the migrating cranial neural crest (Fig. 1f,g ). This elevated expression is seen against a general low level in other regions, which is evident when a TCF11 hybridized embryo is compared with a similar embryo hybridized with a probe for Krox-20, a gene that is expressed very speci®-cally in only two segments of the developing brain at this stage ( Fig. 1e) . At 8.75±9 dpc, TCF11 again shows widespread, low-level expression (Fig. 1d) . There is now a clear dorso-ventral gradient in the level of TCF11 expression in the brain and anterior neural tube (Fig. 1i±m ) while in the posterior embryo, where development is less advanced, there is generally a higher level and more even distribution of expression (Fig. 1m) . Sections at all levels show a pattern consistent with elevated expression in the migrating neural crest. There is expression throughout the developing somites (not shown).
From the in situ analysis it was clear that TCF11 is widely expressed. However, there are some differences in the level of expression in different regions. In order to investigate if there are signi®cant differences in the level of TCF11 expression at later stages of development and/or in different developing organs, we performed semi-quantitative reverse transcription±polymerase chain reaction (RT±PCR). Total RNA was prepared from whole embryos and dissected organs as listed in Fig. 2 . Conditions were optimized using increasing amounts of RNA from each preparation so that a linear relationship existed between amount of template RNA and intensity of the ampli®ed band. For the 14 samples analysed, covering developmental stages from 7.5 to 17.5 dpc, the amount of ampli®cation product is remarkably constant and the ®ndings are reproducible from experiment to experiment (at least three repetitions for each sample) (Fig. 2a,b) .
The absence of strict cell and tissue-speci®c boundaries for TCF11 is in contrast to some other developmentally important transcription factors such as ). TCF11 clearly represents a different class of regulatory gene that is not itself expressed in a highly speci®c manner and any speci®city of function must therefore be controlled at another level. TCF11, as a bZIP protein, can dimerize via its leucine-zipper with other leucine-zipper proteins and dimerization is a general requirement for DNA binding and transcriptional regulation. An important element in the functioning and activity of a bZIP protein is therefore the availability of dimerization partners and differential interaction with such partners. Like its close relative p45-NF-E2 (Andrews et al., 1993; Igarashi et al., 1994) , TCF11 can heterodimerize with products of the small Maf family of proto-oncogenes (Maf G, Maf K and Maf F) and these dimers can bind the NF-E2 site more ef®ciently than TCF11 alone (Johnsen et al., 1996) . Furthermore, using a transient transfection assay we have shown that while TCF11 alone can transactivate expression, co-expression of Maf G interferes with the transactivation (Johnsen et al., 1998) . These results indicate that the activity of TCF11 depends on the cellular context in which it is expressed, which could form the basis for cell speci®c functions.
In addition to small Maf genes, we have recently uncovered an additional candidate partner for TCF11 in a yeast two-hybrid screen. This screen showed dimerization between the bZIP domain of TCF11 and two independent clones of the bZIP factor ATF4 (N. Skammelsrud, in preparation). ATF4 is a member of the activating transcription factor/cAMP responsive element-binding protein family of transcription factors that is know to mediate interaction between speci®c transcription factors and transcriptional co-factors (Liang and Hai, 1997; Fawcett et al., 1999) . ATF4 is widely expressed in adult organs and cell lines but its expression has not previously been described during development. Dimerization of ATF4 and TCF11 in vitro has been con®rmed by immunological detection of an ATF4 containing complex by an anti-TCF11 antibody (N. Skammelsrud, unpublished results).
Like ATF4 (Karpinski et al., 1992) , the Maf factors have been described as widely expressed (Fujiwara et al., 1993; Andrews et al., 1993) . We sought to investigate the developmental expression of these four potential partners in detail in order to obtain some clues to their potential roles in interacting with TCF11 during development. We designed primer pairs for RT±PCR ampli®cation of the murine transcripts, choosing sequences that were unique for each gene. To ensure speci®city of ampli®cation, the normal controls were employed and, in addition, the ampli®ed band was puri®ed, cloned and sequenced, verifying Maf family member or ATF4 identity.
RT±PCR was then performed on the panel of developing mouse RNA preparations that were used in the previous series of experiments. Fig. 2c shows that while MafG is widely expressed, MafK was only detectable in speci®c samples and MafF was not ampli®ed in any of the samples. MafK was not detected at early stages of development, appeared ®rst at 13.5 dpc in liver, and was barely detectable in neural tube, brain and trunk. It was also ampli®ed from 17.5 dpc liver, but not from adult liver, and from heart and brain also at 17.5 dpc but not from limbs at the same stage.
MafF, despite a clean and clear ampli®cation from DNA, showed no ampli®cation from any of the RNA samples and the same results were found with three sets of primer pairs. For ATF4, the transcript was found in all tissues examined. .75 dpc (h±k) and 9 dpc (m) embryos. A, the anterior of the embryo; xe, extraembryonic tissue; e, embryonic tissue; ps, primitive streak; hf, headfold; al, allantois; mb, midbrain; fb, forebrain; hfm, headfold mesenchyme; h, heart; hb, hindbrain; nt, neural tube; s, somites; nc, neural crest; Pos hb, posterior hindbrain; nf, neural folds; cnc, cranial neural crest; b1, branchial arch 1, my, myocardium; nt, neural tube; pos, posterior of embryo;
At early stages of development, when it is feasible to carry out whole mount in situ hybridization, only two of the four candidate partners were detected by RT±PCR. Speci®c probes for in situ hybridization were cloned following PCR ampli®cation and in situ analysis was carried out for MafG, MafK and ATF4 between 7.5 and 9 dpc. MafK, as expected, showed no speci®c labelling at the stages examined (data not shown).
Examples of embryos hybridized with a MafG speci®c probe are shown in Fig. 3 . MafG shows a very widespread and uniform expression at these stages. At 7.5 dpc it is detectable throughout the embryonic and extraembryonic tissues with no obvious differences in the level of expression (Fig. 3a) . At 8.25 dpc there is a more intense labelling of the anterior central nervous system (CNS), with higher levels in the forebrain and midbrain (Fig. 3b) than in the hindbrain and neural tube. There is, however, no sharp boundary to the elevated expression in the anterior CNS. At 8.75±9 dpc (Fig.  3c) , slightly elevated expression in the forebrain and midbrain are still seen. Sections cut from 9 dpc hybridized embryos showed that there is elevated expression in the otic vesicles ( Fig. 3e ) and around the hindgut diverticulum (Fig.  3d) .
ATF4 also showed widespread expression between 7.5 and 10 dpc with some particularly noteworthy details (Fig. Fig. 3 . MafG is widely expressed throughout development. In situ hybridization of mouse embryos at (a) 7.5 dpc, (b) 8.25 dpc and (c) 8.75 dpc with a MafG-speci®c antisense probe. A transverse section in the posterior region (d) and a coronal section through the hindbrain (e) of a 9 dpc embryo. fb, forebrain; mb, midbrain; s, somites; Fb(t), forebrain/telencephalon; r3, rhombomere 3; r5, rhombomere 5; nf, neural folds; hd, hindgut diverticulum; ov, otic vesicle. is expressed relative to the intensity in 7.5 dpc embryos (set at 1) and corrected for the corresponding value for GAPDH ampli®cation. Average values for 10 and 50 ng RNA are shown. 1±14 represent: 1, 7.5 dpc embryos; 2, 8.5 dpc embryos; 3, 9.5 dpc embryos; 4, 10.5 dpc embryos; 5, adult liver; 6, 13.5 dpc liver; 7, 17.5 dpc liver; 8, 13.5 dpc neural tube; 9, 13.5 dpc brain; 10, 17.5 dpc brain; 11, 13.5 dpc heart, 12, 17.5 dpc heart, 13, 13.5 dpc trunk; 14, 17.5 dpc limb. (c) RT±PCR ampli®cation of transcripts of the three small Maf genes; MafG, MafK and MafF, and ATF4. The tissues from which RNA was extracted are indicated above each well. The sizes of each ampli®ed band are indicated on the right. The number of cycles used in ampli®cation are indicated on the left. M, molecular size standard; D, ampli®cation from genomic DNA; 2C, negative control where no reverse transcriptase was added to the reaction. 4). At 7.5 dpc, ATF4 is uniformly expressed throughout the embryo but unlike MafG and TCF11, is more highly expressed in the embryo proper than in extra embryonic membranes (Fig. 4a) . At 8 dpc expression continues to be uniform in the embryo (Fig. 4b) . At 8.25 dpc (Fig. 4c) , however, an elevation in expression level is seen in the anterior CNS, in the prospective midbrain and forebrain and in the anterior head fold mesenchyme and ectoderm. Although sections did not reveal a sharp anterior-posterior (AP) boundary to this elevated domain in the CNS, the whole mount images show that it coincides with, or is slightly posterior to the transition between mesencephalon and prorhombomere A. It is clear in section (Fig. 4g±i) that expression in the migrating cephalic neural crest (OsumiYamashita et al., 1994) contributes largely to this elevated domain, which may explain the lack of a sharp AP boundary. Transverse sections through the hindbrain show that labelling is more intense in the lateral neural folds and the migrating neural crest (Fig. 4h,i) , while in more posterior regions neural tube labelling is uniform (Fig. 4j) . A dorsal view at 8.5 dpc (Fig. 4d) shows the more intense labelling at the lateral edges of the neural folds from which the neural crest cells are migrating. The somites are uniformly labelled (Fig. 4j) .
At 8.75 dpc, a lateral view (Fig. 4e) shows elevated expression in the midbrain and forebrain and a stripe of elevated expression from the hindbrain continuing down into the ®rst branchial arch. At this time, neural crest cells migrate from rhombomere 2 in the hindbrain and contribute to and pattern the developing facial mesenchyme of the ®rst branchial arch. Expression in this population of cells is con®rmed in section (Fig. 4k,m) . A similar but more diffuse elevation is seen from the hindbrain and into the second branchial arch, where neural crest cell migration takes place from rhombomere 4. The heart at this stage does not appear to be strongly labelled in whole mount but sections show that the myocardium is stained (Fig. 4n) . In posterior tail bud regions where the neural folds are still open, expression continues to be uniform (Fig. 4n) . Fig. 4o shows expression in the body wall at the mid trunk level and sections also show that expression in the somites at this and later stages is uniform (Fig. 4p) . Fig. 4f shows expression at 10 dpc when the elevated anterior expression is no longer apparent and expression is now concentrated in posterior regions in the forelimb and particularly the hindlimb bud.
We have limited information about the array of proteins that TCF11 interacts with and there may be many more than we have currently investigated, but the observations presented here show that there are signi®cant differences in the set of potential partner genes expressed at different stages and in different parts of the embryo. This means that while TCF11 is likely to be constantly present in one or several of its forms, the interactions it can form and its relationship with its various potential binding sites can differ from cell to cell. Here we have identi®ed which of its known potential partners may be involved in regulatory interactions in different phases and aspects of development. It is noteworthy that TCF11 and ATF4 show a similar elevation of expression in the migrating neural crest (compare Figs. 1j and 4k) . It is also clear from the RT±PCR analysis that in the developing liver where foetal blood is produced and where TCF11 is essential, three of the four candidates are expressed.
Materials and methods

In situ hybridization
Wild-type embryos at different developmental stages were collected from C57bl6 mice, ®xed from 1 h to overnight (depending on the age of the embryo) in fresh 4% paraformaldehyde in PBS, dehydrated through a series of methanol/PBS solutions and stored at 2208C in 100% methanol. When required, the embryos were re-hydrated and hybridized whole to DIG-labelled probes (after Wilkinson, 1992; Henrique et al., 1995) . Post-hybridization washing was followed by incubation with an alkaline phosphatase coupled anti-DIG polyclonal antibody (Boehringer Mannheim) overnight at 48C. Alkaline phosphatase activity was revealed by supplying NBT/BCIP (75 and 50 mg/ml) (Boehringer Mannheim) as substrate. Staining was carried out for various times, from 1 h to overnight, at 48C.
In situ probes
Sense and antisense RNA probes were produced by incorporating digoxygenin-labelled UTP (DIG-11-UTP) (Boehringer Mannheim) into the in vitro transcription products of various DNA fragments of the genes of interest. The Promega Ribomax kit was used to transcribe from the appropriate promoter in the vector (T3, T7). For analysis of TCF11, four probes were used. (1) from a SacI site (accession no. X78709; bp no. 1444) to the end of the cDNA clone. (2) a SacI/HindIII fragment (1444±2098 bp). (3) from the HindIII site to a HincII site in the 3 H non-coding region (2098±3434 bp). A 535 bp extreme 5 H probe was generated by RT±PCR. For MafG the probe was a 431 bp fragment from the ApaI site (bp 890; accession no. AB009693) to the PstI site (bp 1321) in the 3 H non-coding region. For MafK the probe was a 320 bp fragment from a SacI site (bp 661; accession no. D42124) to a PstI site (bp 982) again in the 3 H non-coding region. For ATF4 a 450 bp fragment from a PstI site (bp 150; accession no. X61507) to a SacI site (bp 605) in the 5 H part of the coding sequence was used as a probe. The probes were hybridized to whole embryos in solution at high stringency (see above).
RT±PCR
Total RNA was prepared from embryos at different developmental stages and from dissected organs at later stages of Fig. 4 . ATF4 expression between 7.5 and 10 dpc. In situ hybridization of whole embryos with an ATF4 speci®c antisense probe. The respective stages are indicated for each embryo and transverse sections of 8.2 dpc (g±j) and 9 dpc embryos (k±p) are shown. e, embryonic tissue; xe, extra-embryonic tissue; hf, headfold; mb, midbrain; fb, forebrain; h, heart; hb, hindbrain; nt, neural tube; s, somites; oc, optic cup; b1, ®rst branchial arch;¯b, forelimb bud; hlb, hindlimb bud; cnc, cranial neural crest; nc, neural crest; nf, neural folds; nt, neural tube; s, somite; my, myocardium; bw, body wall. development using the SV total RNA isolation system (Promega). Speci®c primer pairs were selected for each gene using the software package gene skipper (Christian Schwager, EMBL). The primers used were as follows. TCF11: forward CCCAGAAGCAGTGCCTAGTG, reverse TGCACCCTCAGCCTCTTCTA; MafG: GCCCTGCGC-TCCAAGTAC, reverse AGAGCCCCACTGGACTTC; MafK: forward TGGTTCCGTCCTGGTGAC, reverse CGGCCCCAGCAGACACTA; MafF: forward CAGGT-CAAGCGAGTT, reverse GGGTGGGGGCGGGTACTA; ATF4: forward TCCTCTTCCCCTCCCGCA, reverse CATGTGTCATCCAACGTG; GAPDH: TGAAGGTC-GGTGTGAACGGATTTGGC, reverse GTCCACCACC-CTGTGCTGTA. To keep the conditions standard, the RT±PCR reactions were run using the Access RT±PCR kit (Promega). The cycling conditions were optimized for each primer set. Three total RNA concentrations (10, 50 and 250 ng) were used for each sample to establish the conditions which re¯ect a semi-quantitative relationship between the amount of RNA and the intensity of the ampli®ed band so that the relative amount of TCF11 transcript present in each RNA sample could be estimated. Relative amounts of TCF11 transcript were corrected for the relative amount of GAPDH transcript in each sample. The optical density of the ampli®ed bands was measured using the Multi Analyst package on the Gel Doc 1000 system (Bio Rad).
